Iroko Pharmaceuticals receives FDA approval for Tivorbex

25-02-2014 Business Wire HealthComments (0)

BiotechnologyIrokoPharmaceutical

Related People

Related Companies

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved TIVORBEX (indomethacin) capsules, a nonsteroidal anti-inflammatory drug (NSAID), at 20 mg and 40 mg doses for the treatment of mild to moderate acute pain in adults1. TIVORBEX was approved at dosage strengths that are 20 percent lower than the 25 mg and 50 mg indomethac

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top